MSB $1 Party, page-229

@dgoynich


Thanks for dropping by and kicking us while we're down.
You know full well you have led people to think that AVR's earlier version was going to rocket. It didn't, and the slide has involved colossal consolidations that crystallised losses. Including mine. This has NOT happened with MSB. It's Board is an order of magnitude better than AVR's history.

You clearly don't understand what's going on here and the only response is to DYOR.

This IS the result of the FDA no question. Plus conservatism, Trumpism, cronyism and the rest.

The treatment of inflammation is a revolution in medicine and MSB has been at the forefront. The FDA has chopped and changed its requirements because they simply did not know what to ask for. And the conflict of interest situations where despite a 8-1 recommendation of an expert panel in favour of approval, the decision was taken to delay further. It has been complicated by Covid-19.

Sorry for the death of your mate, but don't come in and unload your bad conscience on us, by encouraging others to sell.

Poor form, to say the least. I'd like to say something less polite.